Summary
Brain iron deposition has been proposed to play an important role in the pathophysiology of Alzheimer disease (AD). The aim of this study was to investigate the correlation of brain iron accumulation with the severity of cognitive impairment in patients with AD by using quantitative MR relaxation rate R2′ measurements. Fifteen patients with AD, 15 age- and sex-matched healthy controls, and 30 healthy volunteers underwent 1.5T MR multi-echo T2 mapping and T2* mapping for the measurement of transverse relaxation rate R2′ (R2′=R2*−R2). We statistically analyzed the R2′ and iron concentrations of bilateral hippocampus (HP), parietal cortex (PC), frontal white matter (FWM), putamen (PU), caudate nucleus (CN), thalamus (TH), red nucleus (RN), substantia nigra (SN), and dentate nucleus (DN) of the cerebellum for the correlation with the severity of dementia. Two-tailed t-test, Student-Newman-Keuls test (ANOVA) and linear correlation test were used for statistical analysis. In 30 healthy volunteers, the R2′ values of bilateral SN, RN, PU, CN, globus pallidus (GP), TH, and FWM were measured. The correlation with the postmortem iron concentration in normal adults was analyzed in order to establish a formula on the relationship between regional R2′ and brain iron concentration. The iron concentration of regions of interest (ROI) in AD patients and controls was calculated by this formula and its correlation with the severity of AD was analyzed. Regional R2′ was positively correlated with regional brain iron concentration in normal adults (r=0.977, P<0.01). Iron concentrations in bilateral HP, PC, PU, CN, and DN of patients with AD were significantly higher than those of the controls (P<0.05); Moreover, the brain iron concentrations, especially in parietal cortex and hippocampus at the early stage of AD, were positively correlated with the severity of patients’ cognitive impairment (P<0.05). The higher the R2′ and iron concentrations were, the more severe the cognitive impairment was. Regional R2′ and iron concentration in parietal cortex and hippocampus were positively correlated with the severity of AD patients’ cognitive impairment, indicating that it may be used as a biomarker to evaluate the progression of AD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci, 1998,158(1):47–52
Bishop GM, Robinson SR, Liu Q, et al. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci, 2002,24(2–3):184–187
Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci, 2004,5(11):863–873
Honda K, Casadesus G, Petersen RB, et al. Oxidative stress and redoxactive iron in Alzheimer’s disease. Ann N Y Acad Sci, 2004,1012:179–182
Smith MA, Harris PLR, Sayre LM, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA, 1997,94(18): 9866–9868
Rottkamp CA, Raina AK, Zhu X, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med, 2001,30(4):447–450
Casadesus G, Smith MA, Zhu X, et al. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis, 2004,6(2): 165–169
Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med, 2004,52(3): 612–618
Zhu WZ, Zhong WD, Wang W, et al. Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer Disease. Radiology, 2009,253(2):497–504
Ordidge RJ, Gorell JM, Deniau JC, et al. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med, 1994,32(3):335–341
Brooks RA, Vymazal J, Goldfarb RB, et al. Relaxometry and magnetometry of ferritin. Magn Reson Med, 1998, 40(2):227–235
Gelman N, Gorell JM, Barker PB, et al. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology, 1999,210(3):759–767
Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntington’s disease. Cell Mol Biol (Noisy-le-grand), 2000,46(4):821–833
Zywicke HA, Van Gelderen P, Connor JR. Microscopic R2* mapping of reduced brain iron in the Belgrade rat. Ann Neurol, 2002,52(1):102–105
Hardy PA, Gash D, Yokel R, et al. Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J Magn Reson Imaging, 2005,21(2):118–127
Hikita T, Kazuo A, Sakoda S, et al. Determination of transverse relaxation rate for estimating iron deposits in the central nervous system. Neurosci Res, 2005,51(1):67–71
Jara H, Sakai O, Mankal P, et al. Multispectral quantitative magnetic resonance imaging of brain iron stores: A theoretical perspective. Top Magn Reson Imaging, 2006, 17(1):19–30
Brass SD, Chen T, Mulkern RV, et al. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging, 2006,17(1):31–40
An H, Lin W. Quantitative measurements of cerebral blood oxygen saturation using magnetic resonance imaging. J Cereb Blood Flow Metab, 2000,20(8):1225–1236
Wallis LI, Paley MNJ, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J Magn Reson Imaging, 2008,28(5):1061–1067
Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem, 1958,3(1):41–51
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 1984,34(7):939–944
Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed, 2004,17(7):433–445
Pankhurst Q, Hautot D, Khan N, et al. Increased levels of magnetic iron compounds in Alzheimer’s disease. J Alzheimers Dis, 2008,13(1):49–52
Thompson CM, Markesbery WR, Ehmann WD, et al. Regional brain trace element studies in Alzheimer’s disease. Neurotoxicology, 1988,9(1):1–8
Deibel MA, Ehmann WD, Markesbery WD. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress. J Neurol Sci, 1996,143(1–2):137–142
Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer’s disease brain. Neurotoxicology, 1998,19(3):339–345
Borthakur A, Gur T, Wheaton AJ, et al. In vivo measurement of plaque burden in a mouse model of Alzheimer’s disease. J Magn Reson Imaging, 2006,24(5):1011–1017
Nakada T, Matsuzawa H, Igarashi H, et al. In vivo visualization of senile-plaque-like pathology in Alzheimer’s disease patients by MR microscopy on a 7T system. J Neuroimaging, 2008,18(2):125–129
Smith MA, Wehr K, Harris PL, et al. Abnormal localization of iron regulatory protein in Alzheimer’s disease. Brain Res, 1998,788(1–2):232–236
Grabill C, Silva AC, Smith SS, et al. MRI detection of ferritin iron overload and associated neuronal pathology in iron regulatory protein-2 knockout mice. Brain Res, 2003,971(1):95–106
Wengenack TM, Jack Jr CR, Garwood M, et al. MR microimaging of amyloid plaques in Alzheimer’s disease transgenic mice. Eur J Nucl Med Mol Imaging, 2008,35(Suppl 1):S82–88
Bartzokis G, Tishler TA, Shin IS, et al. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci, 2004,1012:224–236
House MJ, St Pierre TG, Foster JK, et al. Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. Am J Neuroradiol, 2006,27(2):430–439
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by grants from the National Natural Science Foundation of China (No. 30870702 and No. 30570531) and 863 Project of China (No. 2006AA02Z4A1).
Rights and permissions
About this article
Cite this article
Qin, Y., Zhu, W., Zhan, C. et al. Investigation on positive correlation of increased brain iron deposition with cognitive impairment in Alzheimer disease by using quantitative MR R2′ mapping. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 31, 578–585 (2011). https://doi.org/10.1007/s11596-011-0493-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-011-0493-1